Table 2.
Performance of DAST compared with reference AST method for Enterobacterales by VITEK-2 system
| Enterobacterales (60) | Categorical agreement, n (%) | Categorical disagreement n (%) | Essential agreement | ||||
|---|---|---|---|---|---|---|---|
| Minor error | Major error | Very major error | Total | Agreed | Disagreed | ||
| Cefoperazone sulbactam | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Amoxicillin/clavulanic acid | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Piperacillin/tazobactam | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Cefuroxime | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Cefuroxime axetil | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Cefepime | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Ceftriaxone | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Imipenem | 54 (90.0%) | 2 (3.3%) | 4 (6.7%) | 0 (0.0%) | 6 (10.0%) | 57 (95%) | 3 (5.0%) |
| Meropenem | 59 (98.3%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (1.7%) | 58 (96.7%) | 2 (3.3%) |
| Amikacin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Gentamicin | 59 (98.3%) | 0 (0.0%) | 1 (1.7%) | 0 (0.0%) | 1 (1.7%) | 58 (96.7%) | 2 (3.3%) |
| Ciprofloxacin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100%) | 0 (0.0%) |
| Tigecycline | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |
| Colistin | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |
| Cotrimoxazole | 60 (100.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 60 (100.0%) | 0 (0.0%) |